WINTON GROUP Ltd boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 7,674 shares of the biopharmaceutical company’s stock after acquiring an additional 1,079 shares during the quarter. WINTON GROUP Ltd’s holdings in Gilead Sciences were worth $579,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Cypress Capital Group grew its stake in Gilead Sciences by 6.4% in the 1st quarter. Cypress Capital Group now owns 43,799 shares of the biopharmaceutical company’s stock valued at $3,302,000 after acquiring an additional 2,621 shares during the period. Handelsbanken Fonder AB boosted its stake in Gilead Sciences by 19.4% during the 1st quarter. Handelsbanken Fonder AB now owns 239,870 shares of the biopharmaceutical company’s stock worth $18,084,000 after purchasing an additional 39,000 shares during the last quarter. Catalyst Capital Advisors LLC boosted its stake in Gilead Sciences by 6.7% during the 1st quarter. Catalyst Capital Advisors LLC now owns 50,514 shares of the biopharmaceutical company’s stock worth $3,808,000 after purchasing an additional 3,165 shares during the last quarter. Wesbanco Bank Inc. boosted its stake in Gilead Sciences by 42.8% during the 1st quarter. Wesbanco Bank Inc. now owns 37,474 shares of the biopharmaceutical company’s stock worth $2,825,000 after purchasing an additional 11,238 shares during the last quarter. Finally, CIBC World Markets Inc. boosted its stake in Gilead Sciences by 19.6% during the 1st quarter. CIBC World Markets Inc. now owns 782,580 shares of the biopharmaceutical company’s stock worth $58,999,000 after purchasing an additional 128,419 shares during the last quarter. 77.67% of the stock is currently owned by hedge funds and other institutional investors.

Shares of GILD opened at $71.33 on Thursday. The stock has a market capitalization of $92.75 billion, a P/E ratio of 9.25, a P/E/G ratio of -6.18 and a beta of 1.12. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.67 by ($0.19). The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm’s quarterly revenue was down 21.8% on a year-over-year basis. During the same quarter last year, the firm posted $2.23 earnings per share. analysts expect that Gilead Sciences, Inc. will post 5.77 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 28th. Investors of record on Friday, June 15th were issued a $0.57 dividend. The ex-dividend date of this dividend was Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.20%. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.

Several equities research analysts have issued reports on GILD shares. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 6th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Thursday, April 19th. Barclays lowered their target price on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 2nd. Piper Jaffray Companies started coverage on shares of Gilead Sciences in a research note on Wednesday, May 30th. They set a “buy” rating and a $85.00 target price on the stock. Finally, Leerink Swann set a $72.00 target price on shares of Gilead Sciences and gave the stock a “market perform” rating in a research note on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $88.22.

In related news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $72.19, for a total value of $3,609,500.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $221,461,738.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Friday, April 13th. The shares were sold at an average price of $75.56, for a total transaction of $440,741.48. Following the completion of the sale, the director now owns 58,452 shares in the company, valued at $4,416,633.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 129,168 shares of company stock worth $9,132,233. 1.30% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.